Goldman Sachs analyst Corinne Jenkins maintained a Hold rating on Ambrx Biopharma (AMAM – Research Report) today and set a price target of $4.00. The company's shares closed last Monday at $4.09, close to its 52-week low of $3.33. According to TipRanks.com, Jenkins is a 1-star analyst with an average return of -10.4% and a 50.0% success rate. Jenkins covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Rhythm Pharmaceuticals, and Bioxcel Therapeutics. Ambrx Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
https://www.tipranks.com/news/blurbs/ambrx-biopharma-amam-receives-a-hold-from-goldman-sachs?utm_source=advfn.com&utm_medium=referral
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Aug 2022 bis Sep 2022 Click Here for more Ambrx Biopharma Charts.
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Sep 2021 bis Sep 2022 Click Here for more Ambrx Biopharma Charts.